| Type of Capital Measure | Date (MM/DD/JJ) | Gross proceeds (Mio. €) | Issue price (€) | Total number of shares after issuance | Number of shares issued |
| Capital Increase against Cash | 24.05.18 | 32.3 | 14.50 | 24,544,595 | 2,230,000 |
| Capital Increase in Kind (acquisition of Trianta) | 18.09.17 | 2.0 | 10.9687 | 22,300,947 | 182,335 |
| Capital Increase against Cash | 08.05.17 | 20.7 | 10.55 | 22,118,329 | 1,964,599 |
| Termination of convertible bond program issued on July 21, 2014 | 21.07.16 | 20,136,887 | 167,164 | ||
| Capital Increase in Kind (acquisition of Trianta) | 20.05.16 | 3.2 | 8.08 | 20,081,835 | 392,875 |
| Capital Increase against Cash | 03.07.15 | 46.4 | 8.30 | 19,645,993 | 5,594,178 |
| Capital Increase in Kind (acquisition of Trianta) | 16.06.15 | 0.7 | 10.55 | 14,051,815 | 66,370 |
| Issuance of 818,658 convertable bonds | 21.07.14 | 0.8 | 1.00 | ||
| Capital Increase against Cash | 17.07.14 | 15.1 | 5.00 | 13,906,032 | 3,016,082 |
| Capital Increase in Kind (acquisition of Trianta) | 12.03.14 | 4.0 | 3.93 | 10,889,950 | 1,017,811 |
| Share capital reduction | 29.10.13 | 9,872,139 | |||
| Capital Increase against Cash | 29.05.13 | 2.4 | 1.00 | 39,488,558 | 2,405,800 |
| Capital Increase against Cash (Seda2)) | 30.06.10 | 1.5 | 2.55 | 37,082,758 | 588,235 |
| Capital Increase against Cash (Seda2)) | 04.05.10 | 1.0 | 2,76 | 36,494,523 | 362,318 |
| Capital Increase against Cash (Seda2)) | 24.03.10 | 2.0 | 3.48 | 36,132,205 | 574,712 |
| Capital Increase against Cash (Seda2)) | 11.12.09 | 2.0 | 3.52 | 35,557,493 | 568,181 |
| Capital Increase against Cash (Seda2)) | 18.11.09 | 2.0 | 3.94 | 34,989,312 | 507,614 |
| Capital Increase against Cash (Seda2)) | 02.11.09 | 1.0 | 4.46 | 34,481,698 | 224,215 |
| Capital Increase against Cash (Seda2)) | 13.10.09 | 1.0 | 4.87 | 34,257,483 | 205,338 |
| Capital Increase against Cash | 03.06.09 | 0.1 | 4.24 | 34,052,145 | 23,584 |
| Capital Increase against Cash | 10.09.07 | 15.6 | 5.05 | 33,927,121 | 3,084,282 |
| Capital Increase against Cash | 14.02.07 | 12.6 | 6.10 | 30,842,839 | 2,062,040 |
| Acquisition of Avidex Ltd. | 27.09.06 | 50.1 | 6.00 | 28,651,070 | 8,157,787 |
| Capital Increase against Cash | 02.03.06 | 15.7 | 8.45 | 20,620,452 | 1,852,260 |
| Conversion of all outstanding bonds issued on March 24, 2004 | 16.12.05 | 7.48 | 18,722,666 | 199,982 | |
| Capital Increase against Cash | 15.11.04 | 21.6 | 7.00 | 18,522,684 | 3,087,114 |
| Acquisition of the Assets of Munich Biotech AG | 13.08.04 | 11.3 | 5.76 | 15,435,170 | 1,960,938 |
| Issuance of Convertible Bonds at a Price of 1 € each | 24.03.04 | 1.5 | 1.00 | 13,474,032 | |
| Capital Increase against Cash | 24.03.04 | 15.3 | 6.80 | 13,474,032 | 1,122,835 |
| 1,122,835 | |||||
| 1.5 1) | 7.50 1) | ||||
| Acquisition NeuroVir | 12.01.01 | 90.2 | 90.50 | 11,162,288 | 996,631 |
| IPO/Capital Increase against Cash | 30.06.00 | 125.4 | 42.00 | 10,100,000 | 2,985,354 |
| 1) Issuance of 1,500,000 convertible bonds at a price of 1 € each 2) SEDA: Standby Equity Distribution Agreement | |||||
